The underlying technology platform at Veloxis was developed to address a critical roadblock experienced by pharmaceutical companies related to poor oral absorption (bioavailability) of otherwise high-potential drugs.
Faced with the problems of new drug substances with low water solubility, H. Lundbeck A/S decided to put forth a focused effort into the development and implementation of dissolution- and absorption-enhancing methods. The ground-breaking work resulted in the development of a unique technology that improves the bioavailability of low water-soluble or -insoluble drug substances so that these drugs can be taken orally.
To capitalize on its potential, H. Lundbeck A/S decided to spin out this technology into LifeCycle Pharma A/S, which was formed in June 2002.
In July 2011, LifeCycle Pharma became Veloxis Pharmaceuticals A/S.
BUSINESS DEVELOPMENT CONTACT:
John Weinberg, EVP, CCO
Telephone: +1 732-321-3208